MEETING MINUTES

Members Present: Tracy Klein, PhD, FNP; William Origer, MD; David Pass, MD; James Slater, PharmD
Members Present by Phone: Andris Antoniskis, MD; Joshua Bishop, PharmD
Staff Present: Roger Citron, RPh; Megan Herink, PharmD, BCPS; Kathy Ketchum, RPh, MPA; HA; Valerie Smith, Trevor Douglass, DC, MPH
Staff Present by Phone: Bing-Bing Liang, PharmD; Kathy Sentena, PharmD
Audience: Ann Neilson (Amgen); Vinson Lee (Amgen); Jamie Tobitt (Vertex); Paul Setlak (Abbott); Bob Snediker (Janssen); Jamie Damnn (Vertex); Jeff Gold; Jean Colabianchi; Anne Marie Licos (MedImmune); Bruce Smith; Cheryl Fletcher (Abbott); Mike Murphy (Abbott); Craig Black (Biogen Idec); Diann Matthews (J&J); Brad (Elan); Steve Faloon (Otsuka); Amy Burns (OSU); Lauren Armijo (OSU); Amanda Meeker (OSU); Chelsea Smith (OSU)

NOTE: Any agenda items discussed by the DUR/P&T Committee may result in changes to coverage, PDL composition, or utilization control recommendations to the OHA. Timing, sequence and inclusion of agenda items presented to the Committee may change at the discretion of the OHA, P&T Committee and staff.

I. CALL TO ORDER
   a. The meeting was called to order at approximately 1:15pm.
   b. Conflict of interest declarations were reviewed and no new conflicts were reported.
   c. The June 28, 2012 meeting minutes were reviewed and it was noted that the minutes are correct; however the recommendations posted by Dr. Goldberg held a discrepancy. Lovaza was made non-preferred and the recommendation on fish oil was deferred.

ACTION: Minutes approved and directed staff to correct Lovaza recommendations with June posting.

II. OLD BUSINESS
   a. Dr. Herink presented fidaxomicin (Dificid®) infectious disease consult from Dr. James Leggett and recommended continuation of previously recommended PA criteria.

*ACTION: All in favor.

   b. Dr. Sentena presented a new drug evaluation for ivacaftor (Kalydeco®). Jamie Tobill from Vertex presented public comment. Dr. Jeffrey Gold with OHSU Cystic Fibrosis Center presented public comment.

*ACTION: All in favor after executive session with recommendations to implement PA with discussed updates and consult HERC for guidance on appropriate resource allocations.

III. NEW BUSINESS
   a. Ms. Ketchum presented ESA class update and new drug review recommending peginesatide (Omontys®) non-preferred, limiting all to appropriate use per PA criteria and verify response at 8 weeks, and recommending the HERC update guideline note 7 with current FDA labeling. Robert Snediker with Janssen presented public comment. Vincent Lee from Amgen presented public comment.

*Agenda items will be discussed by Committee members for the purpose of making recommendations to the Oregon Health Plan for adoption into Oregon Administrative Rules 410-121-0030 & 410-121-0040 as required by 414.325(9)
**ACTION:** All in favor after executive session with deferment of darbepoetin and epoetin status until September meeting to wait for supplemental rebate negotiations.

b. Dr. Liang presented nitrates abbreviated class review and new drug evaluation recommending PA criteria and the addition of nitrates to the PDL to include a short acting nitrate for angina prevention and treatment including sublingual tablets, isosorbide dinitrate tablets and sublingual tablets and isosorbide mononitrate tablets. Add a long acting nitrate for angina prophylaxis and treatment of angina and include isosorbide dinitrate ER for the management of heart failure including isosorbide mononitrate ER 24H tablets, isosorbide dinitrate ER capsules, nitroglycerin ER capsules and nitroglycerine patches. Make recommended making isosorbide dinitrate ER tablets, nitroglycerin spray and ointments, including nitroglycerin ointment 0.4% (Rectiv®) non-preferred and implement PA criteria to limit use to funded diagnoses.

**ACTION:** All in favor after executive session.

c. Dr. Herink presented targeted immune modulators (TIMS) drug class review recommending maintain the most recently approved TIMS golimumab, tocilizumab and ustekinumab as non-preferred TIMS, consider additional clinical criteria for prior authorization of non-preferred TIMS including a step therapy requirement with a trial of methotrexate first for RA and limited to the appropriate FDA indications for each non-preferred drug and consider a DUE to evaluate preferred products for off-label use or use inconsistent with current clinical guidelines. Keep Humira and Enbrel as preferred, make ustekinumab and infliximab non-preferred and recommend closing natalizumab, infliximab, rituximab and tocilizumab to drug claims and require J-code billing.

**ACTION:** All in favor after executive session.

d. Dr. Willard presented the new drug review for deferiprone (Ferriprox®) recommending the addition of deferoxamine as preferred on the PDL and making the oral agents deferasirox and deferiprone non-preferred and use current PDL PA criteria to utilize them as second line agents.

**ACTION:** All in favor after executive session.

V. ADJOURN
The meeting adjourned at approximately 3:50pm. The next meeting will be in Wilsonville on August 30, 2012.

*Agenda items will be discussed by Committee members for the purpose of making recommendations to the Oregon Health Plan for adoption into Oregon Administrative Rules 410-121-0030 & 410-121-0040 as required by 414.325(9)